Patients with wet age-related macular degeneration who received a Port Delivery System with a 100 mg/mL dose of ranibizumab had similar vision and anatomic outcomes as patients who received monthly intravitreal injections of ranibizumab.
“The PDS has the potential to reduce intravitreal injection treatment burden and improve real-world clinical study outcomes in patients with neovascular macular degeneration,” David A. Eichenbaum, MD, said at the virtual American Society of Retina Specialists meeting.
The LADDER phase 2 trial included 220 patients randomly assigned to receive the
Uncategorized